Needham Reiterates Buy on NeoGenomics, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a 'Buy' rating on NeoGenomics (NASDAQ:NEO) and maintained a price target of $21.
November 07, 2023 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a 'Buy' rating on NeoGenomics, maintaining a price target of $21. This could potentially boost investor confidence in the stock.
Analyst ratings often influence investor sentiment. A reiterated 'Buy' rating indicates that the analyst continues to have confidence in the company's performance. This could potentially lead to increased demand for the stock, driving up its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100